Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
First Claim
Patent Images
1. A method for treatment of a cardiac dysfunction which comprises administering, to a subject in need of such treatment, a cardiac dysfunction treatment effective amount of a 15-ketoprostaglandin compound represented by formula (I):
- ##STR9## wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at lest one double bond, Z is hydrogen or halo, A is --CH2 OH, --COCH2 OH, --COOH or its functional derivative, B is --CH2 --Ch2, --CH═
CH-- or --C.tbd.C--, R1 is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R2 is saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alky, aryl or aryloxy, and said compound represented by formula (I) having at least one of (i) a halogen atom at position 5 or 16 or at positions 5 and 16 and (ii) a lower alkyl at position 19.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for treatment of a cardiac dysfunction which comprises administering, to a subject in need of such treatment, a 15-ketoprostaglandin compound in an amount effective in treatment of the cardiac dysfunction.
-
Citations
14 Claims
-
1. A method for treatment of a cardiac dysfunction which comprises administering, to a subject in need of such treatment, a cardiac dysfunction treatment effective amount of a 15-ketoprostaglandin compound represented by formula (I):
- ##STR9## wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at lest one double bond, Z is hydrogen or halo, A is --CH2 OH, --COCH2 OH, --COOH or its functional derivative, B is --CH2 --Ch2, --CH═
CH-- or --C.tbd.C--, R1 is bivalent saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, oxo or aryl, R2 is saturated or unsaturated, lower or medium aliphatic hydrocarbon residue which is unsubstituted or substituted with halo, hydroxy, oxo, lower alkoxy, lower alkanoyloxy, cyclo(lower)alky, aryl or aryloxy, and said compound represented by formula (I) having at least one of (i) a halogen atom at position 5 or 16 or at positions 5 and 16 and (ii) a lower alkyl at position 19. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- ##STR9## wherein X and Y are hydrogen, hydroxy, halo, lower alkyl, hydroxy(lower)alkyl, or oxo, with the proviso that at least one of X and Y is a group other than hydrogen, and 5-membered ring may have at lest one double bond, Z is hydrogen or halo, A is --CH2 OH, --COCH2 OH, --COOH or its functional derivative, B is --CH2 --Ch2, --CH═
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeSucampo AG (Mallinckrodt plc)
-
Original AssigneeKabushikikaisha UENO Seiyaku OYO Kenkyujo
-
InventorsUeno, Ryuji, Osama, Hiroyoshi
-
Primary Examiner(s)Waddell, Frederick E.
-
Assistant Examiner(s)JARVIS, WILLIAM R A
-
Application NumberUS07/892,640Time in Patent Office511 DaysField of Search514/573US Class Current514/573CPC Class CodesA61K 31/557 Eicosanoids, e.g. leukotrie...
